Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

February 2015

Prior Authorization Required for Otezla 

Beginning April 1, 2015, Harvard Pilgrim will require prior authorization for coverage of the medication Otezla (apremilast), which was approved by the FDA for the treatment of active psoriatic arthritis in adults last year. However, prior authorization will not be required for members who have filled a prescription for Otezla in the previous 6 months.

Harvard Pilgrim’s Otezla Clinical Coverage Criteria detail the requirements that must be met in order to obtain prior authorization, including:

  • Patient is 18 years of age or older.
  • Diagnosis of active psoriatic arthritis or moderate to severe plaque psoriasis.
  • For patients with active psoriatic arthritis:
    • Prescribed by (or in consultation with) a rheumatologist or dermatologist.
    • Patient has tried and failed therapy with, or has a contraindication to a DMARD (disease-modifying anti-rheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine.
  • For patients with moderate to severe plaque psoriasis:
    • Prescribed by (or in consultation with) a dermatologist.
    • Patient has tried at least one course of systemic therapy for psoriasis including (but not limited to) acitretin, azathioprine, cyclosporine, hydroxyurea, methotrexate, mycophenolate mofetil, oral methoxsalen plus UVA light (PUVA), propylthiouracil, sulfasalazine, tacrolimus, or 6-thioguanine.
  • Patient has tried and failed therapy with, or has a contraindication to Humira or Enbrel.

    Approvals will be valid for 12 months. Harvard Pilgrim requires the following for a prior authorization to be renewed: the medication is prescribed by or in consultation with a dermatologist or rheumatologist, the patient has been diagnosed with psoriatic arthritis or plaque psoriasis, and symptoms have improved while the patient is on Otezla therapy.

    Otezla is covered on Harvard Pilgrim’s Premium formularies only at the highest tier (i.e., Tier 3 on the 3-Tier and Tier 4 on the 4-Tier) and must be obtained through Accredo. To request prior authorization, please complete the Otezla Medication Request Form and fax it to MedImpact HealthCare Systems at 888-807-6643. For more information, please refer to the Pharmacy section of Harvard Pilgrim’s provider website.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Reminder: CAQH Switching to New Version February 24-March 2

Data Sharing Enhancements


Coverage of New Hepatitis C Medication Harvoni

Fentanyl Patch and Xartemis XR Quantity Limit

Granix Now Covered Under Pharmacy Benefit

Prior Authorization Required for Afrezza

Prior Authorization Required for Otezla

Tier Increase for Rebif on Premium Formularies

Caring for a Caregiver: Signs and Treatment of Caregiver Stress


Update to CPT and HCPCS Level II Modifiers Payment Policy

Urgent Care Network Requirements


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator